Positron emission tomography (PET) and single photon emission computed tomography (SPECT): Clinical applications

Journal of Neuro-Ophthalmology

Volumn 23, Issue 1, 2003, Pages 34-41

  Blake, Pamela ^a   Johnson, Britta ^a   VanMeter, John W ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; EUROLITE; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; THALLIUM 201;

ARTICLE; BRAIN BLOOD FLOW; BRAIN CANCER; COST EFFECTIVENESS ANALYSIS; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EPILEPSY; IMAGE ANALYSIS; MIGRAINE; MOTOR DYSFUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE; VISUAL CORTEX; VISUAL IMPAIRMENT;

BRAIN DISEASES; BRAIN MAPPING; CLINICAL LABORATORY TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VISUAL CORTEX;

EID: 0037336140     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041327-200303000-00009     Document Type: Article

References (44)

1. Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661-81.
2. The Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Assessment of brain SPECT. Neurology. 1996;46:278-85.
3. Thrall B. Single-Photon Emission Computed Tomography and Positron Emission Tomography. In: Thrall JH, Zeissman HA, eds. Nuclear Medicine: The Requisites. St. Louis: Mosby, 2001:33-47.
4. Zeissman HE. Central Nervous System. In: Thrall JH, Zeissman HA, eds. Nuclear Medicine: The Requisites. St. Louis: Mosby, 2001:294-321.
5. Kuhl DE, Edwards RQ. The Mark 3 Scanner: a compact device for multiple-view and section scanning of the brain. Radiology 1970; 96:563-70.
6. Ter-Pogossian MM, Phelps ME, Hoffman EJ, et al. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology 1975;114(1):89-98.
7. Coleman RE. Clinical PET: role in diagnosis and management. J Nucl Med 2000;41:36N-42N.
8. Sokoloff L. Circulation and energy metabolism of the brain. In: Siegel G, Agranoff B, Albers RW, Molinoff P, eds. Basic Neurochemistry, 4th edn, New York, NY: Raven, 1989:565-90.
9. Sokoloff L. Relationship between functional activity and energy metabolism in the nervous system: whether, where and why. In: Lassen NA, Ingvar DH, Raichle ME, Friberg L, eds. Brain Work and Mental Activity: Quantitative Studies with radioactive tracers-Alfred Benzon Symposium VIII, Vol 31. Copenhagen, Denmark: Munksgaard; 1991:52-67.
10. Hustinx R, Alavi A. SPECT and PET imaging ofbrain tumors. Neuroimaging Clin N Am 1999;9(4):751-66
11. Phelps ME. Positron emission tomography provides molecular imaging of biologic processes. Proc Natl Acad Sci USA 2000;97(16): 9226-33
12. Schaefer PW, Budzik RF Jr., Gonzalez RG. Imaging of cerebral metastases. Neurosurg Clin North Amer 1996;7(3):313-23
13. 18F]fluorodeoxygluxose in recurrent colorectal cancer. Br J Surg 1994;81:1666-70.
14. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803-9.
15. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-6.
16. 18F]fluorodeoxygluxose positron emission tomography. Cancer 1998;82:1664-71.
17. Gupta NC, Nicholson P, Bloomfield SM. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors. Ann Surg 1999;230(2):202-6.
18. Maria BL, Drane WE, Quisling RG: Value of thallium-201 SPECT imaging in childhood brain tumors. Pediatr Neurosurg 1994;20:11-8.
19. Skiest D, Erdman W, Chang W, et al. use of thallium-201 SPECT scanning and Toxoplasma serology for presumptive diagnosis of CNS lesions in patients with AIDS. Int Conf Aids 1998;12:1049.
20. Dickson DW. Alzheimer's disease and dementia. Clin Ger Med 2001;17(2):209-28.
21. Minoshima J, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42(1):85-94.
22. Steinling M, Defebvre L, Duhamel A, et al. Is there a typical pattern of brain SPECT imaging in Alzheimer's Disease? Dement Geriatr Cogn Disord 2001;12(6):371-8.
23. Falconer J, Wada JA, Martin W, et al. PET, CT, and MRI imaging of neuronal migration anomalies in epileptic patients. Can J Neurol Sci 1990;17(1):35-9.
24. Silverman IE, Galetta SL, Gray LG, et al. SPECT in patients with cortical visual loss. J Nucl Med 1993;34(9):1447-51.
25. Moster ML, Galetta SL, Schatz NJ. Physiologic imaging in "functional" visual loss. Surv Ophthalmol 1996;40(5):395-9.
26. Drubach DA, Carmona S, Mayerrose GE, et al. Brain SPECT in a case of cortical blindness. Stroke 1994;25(5):1061-4.
27. Lauritzen M. Cortical spreading depression in migraine. Cephalalgia 2001;21(7):757-60.
28. Woods R, Jacoboni M, Mazziotta J. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994;331:1689-92.
29. Bednarczyk EM, Remler B, Weikart C. Global cerebral blood flow, blood volume, and oxygen metabolism in patients with migraine headache. Neurology 1998;50(6):1736-40.
30. Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet 2001;357(9261):1016-7.
31. May A, Bahru A, Buchel C, et al. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 2000;55(0): 1328-35.
32. Mellies JK, Baumer T, Muller JA. SPECT study of a German CADASIL family. Neurology 1998;50(6):1715-21.
33. Esmaeli-Gutstein B, Nahmias C, Thompson M, et al. Positron emission tomography in patients with benign essential blepharospasm. Ophthal Plast Reconstr Surg 1999;15(1):23-7.
34. Martin WRW. Parkinson's Disease: Positron emission tomographic studies. Semin Nerol 1989;9:351-6
35. Anouti A, Koller WC. Diagnostic testing in movement disorders. Neurol Clin 1996;14(1):169-82.
36. Zeki S, Watson JD, Lueck CJ, et al. A direct demonstration of functional specialization in human visual cortex. J Neurosci 1991;11(3): 641-9.
37. Cohen LG, Weeks RA, Sadato N. Period of susceptibility for crossmodal plasticity in the blind. Ann Neurol 1999;45(4):451-60.
38. Kosslyn SM, Thompson WL, Costantini-Ferrando MF, et al. Hypnotic visual illusion alters color processing in the brain. Am J Psychiatry 2000;157(8):1279-84
39. Belliveay JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med 1990;14 (3):538-46
40. Kwong KK, Belliveau JW, Chesler DA, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci USA 1992;89(12):5675-9.
41. Logothetis NK, Pauls J, Auguth M. Neurophysiologiv investigation of the basis of the fMRI signal. Nature 2001;412(6843): 150-7.
42. Wilson AA, Ginovart N, Hussey D, et al. In vitro and in vivo characterization of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter in positron emission tomography. Nucl Med Biol 2002;29(5):509-15
43. Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorders. Br J Psychiatry 2001;179:390-6
44. Arajuo DM, Cherry SR, Tatsukawa KJ, et al. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's Disease. Exp Neurol 2000;166(2):287-97